Your browser doesn't support javascript.
Early Prognostic Indicators of Subsequent Hospitalization in Patients with Mild COVID-19.
Ylescupidez, Alyssa; Rips, Aaron; Bahnson, Henry T; Speake, Cate; Verma, Punam; Hocking, Anne M; Buckner, Jane H; Malhotra, Uma.
  • Ylescupidez A; Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Rips A; Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Bahnson HT; Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Speake C; Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Verma P; Department of Microbiology, Virginia Mason Medical Center, Seattle, WA 98101, USA.
  • Hocking AM; Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Buckner JH; Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.
  • Malhotra U; Department of Infectious Disease, Virginia Mason Medical Center, Seattle, WA 98101, USA.
J Clin Med ; 10(8)2021 Apr 08.
Article in English | MEDLINE | ID: covidwho-1526821
ABSTRACT
Comprehensive data on early prognostic indicators in patients with mild COVID-19 remains sparse. In this single center case series, we characterized the initial clinical presentation in 180 patients with mild COVID-19 and defined the earliest predictors of subsequent deterioration and need for hospitalization. Three broad patient phenotypes and four symptom clusters were characterized, differentiated by varying risk for adverse outcomes. Among 14 symptoms assessed, subjective shortness of breath (SOB) most strongly associated with adverse outcomes (odds ratio (OR) 21.3, 95% confidence interval (CI) 2.7-166.4; p < 0.0001). In combination, SOB and number of comorbidities were highly predictive of subsequent hospitalization (area under the curve (AUC) 92%). Additionally, initial lymphopenia (OR 21.0, 95% CI 2.1-210.1; p = 0.002) and male sex (OR 3.5, 95% CI 0.9-13.0; p = 0.05) were associated with increased risk of poor outcomes. Patients with known comorbidities, especially multiple, and those presenting with subjective SOB or lymphopenia should receive close monitoring and consideration for preemptive treatment, even when presenting with mild symptoms.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Jcm10081562

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Jcm10081562